Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 751

Results For "ED"

9043 News Found

AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
Biotech | March 11, 2022

AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment

Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally


Cancer surgeons gather in Delhi to learn new cancer therapies
Public Health | March 11, 2022

Cancer surgeons gather in Delhi to learn new cancer therapies

Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system


Strides receives USFDA approval for Colchicine tablets
Drug Approval | March 11, 2022

Strides receives USFDA approval for Colchicine tablets

Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout


USFDA approves Lupin’s Vigabatrin oral solution
Drug Approval | March 11, 2022

USFDA approves Lupin’s Vigabatrin oral solution

The product will be manufactured at Lupin’s facility in Goa, India


Moderna begins Phase 2 study of Omicron-specific bivalent booster
Biotech | March 11, 2022

Moderna begins Phase 2 study of Omicron-specific bivalent booster

Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine


Aurobindo Pharma trains its managers to be `future ready’
News | March 11, 2022

Aurobindo Pharma trains its managers to be `future ready’

Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready


Emmes acquires Casimir, its fourth major acquisition
Biotech | March 11, 2022

Emmes acquires Casimir, its fourth major acquisition

Casimir further differentiates Emmes’ industry-leading rare disease research capabilities


First-in-human trial in US for Gan & Lee type 2 diabetes drug
Biotech | March 11, 2022

First-in-human trial in US for Gan & Lee type 2 diabetes drug

The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers


Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals
interviews | March 10, 2022

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma


Gufic Biosciences collaborates with Selvax for cancer treatment
Biotech | March 10, 2022

Gufic Biosciences collaborates with Selvax for cancer treatment

Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours